Potential of Nanoparticulate Drug Delivery Systems by Intranasal Administration

被引:87
作者
Ali, Javed [1 ]
Ali, Mushir [1 ]
Baboota, Sanjula [1 ]
Sahni, Jasjeet Kaur [1 ]
Ramassamy, Charles [2 ]
Dao, Le [3 ]
Bhavna [1 ]
机构
[1] Jamia Hamdard, Dept Pharmaceut, Fac Pharm, New Delhi 110062, India
[2] INRS Inst Armand Frappier, Quebec City, PQ, Canada
[3] INRS EMT, Quebec City, PQ, Canada
关键词
Intranasal delivery; nanoparticulate system; vaccine delivery; systemic delivery; topical delivery; brain delivery; COMPACTED DNA NANOPARTICLES; CHITOSAN BASED FORMULATIONS; CENTRAL-NERVOUS-SYSTEM; RAT NASAL CAVITY; CEREBROSPINAL-FLUID; MUCOADHESIVE MICROEMULSIONS; CLEARANCE CHARACTERISTICS; TARGETING EFFICIENCY; PLA NANOPARTICLES; MOLECULAR-WEIGHT;
D O I
10.2174/138161210791164108
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Due to number of problems related with oral, parenteral, rectal and other routes of drug administration, the interest of pharmaceutical scientists has increased towards exploring the possibilities of intranasal delivery of various drugs. Nasal drug delivery system is commonly known for the treatment of local ailments like cold, cough, rhinitis, etc. Efforts have been made to deliver various drugs, especially peptides and proteins, through nasal route for systemic use; utilizing the principles and concepts of various nanoparticulate drug delivery systems using various polymers and absorption promoters. The incorporation of drugs into nanoparticles might be a promising approach, since colloidal formulations have been shown to protect them from the degrading milieu in the nasal cavity and facilitate their transport across the mucosal barriers. The use of nanoparticles for vaccine delivery provides beneficial effect, by achieving good immune responses. This could be due to the fact that small particles can be transported preferentially by the lymphoid tissue of the nasal cavity (NALT). The brain gets benefited through the intranasal delivery as direct olfactory transport bypasses the blood brain barrier and nanoparticles are taken up and conveyed along cell processes of olfactory neurons through the cribriform plate to synaptic junctions with neurons of the olfactory bulb. The intranasal delivery is aimed at optimizing drug bioavailability for systemic drugs, as absorption decreases with increasing molecular weight, and for drugs, which are susceptible to enzymatic degradation such as proteins and polypeptides. This review discusses the potential benefits of using nanoparticles for nasal delivery of drugs and vaccines for brain, systemic and topical delivery. The article aims at giving an insight into nasal cavity, consideration of factors affecting and strategies to improve drug absorption through nasal route, pharmaceutical dosage forms and delivery systems with examples of some patents for intranasal delivery, its advantages and limitations.
引用
收藏
页码:1644 / 1653
页数:10
相关论文
共 90 条
[1]   Nanoparticles as Novel Carrier for Brain Delivery: A Review [J].
Agarwal, Abhinav ;
Lariya, Narendra ;
Saraogi, Gauravkant ;
Dubey, Nidhi ;
Agrawal, Himanshu ;
Agrawal, G. P. .
CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (08) :917-925
[2]  
BENDE M, 1983, EUR J RESPIR DIS, V64, P400
[3]   Biovector™ nanoparticles improve antinociceptive efficacy of nasal morphine [J].
Betbeder, D ;
Sperandio, S ;
Latapie, JP ;
de Nadai, J ;
Etienne, A ;
Zajac, JM ;
Frances, B .
PHARMACEUTICAL RESEARCH, 2000, 17 (06) :743-748
[4]   MEASUREMENT OF SECRETION IN NASAL LAVAGE [J].
BISGAARD, H ;
KROGSGAARD, OW ;
MYGIND, N .
CLINICAL SCIENCE, 1987, 73 (02) :217-222
[5]  
BROFELDT S, 1983, EUR J RESPIR DIS, V64, P436
[6]   FINE STRUCTURE OF BLOOD VESSELS OF HUMAN NASAL RESPIRATORY MUCOSA [J].
CAUNA, N ;
HINDERER, KH .
ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 1969, 78 (04) :865-&
[7]  
CHEIN YW, 1989, NASAL SYSTEMIC DRUG, P26
[8]   In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery [J].
Chen, Fu ;
Zhang, Zhi-Rong ;
Yuan, Fang ;
Qin, Xuan ;
Wang, Minting ;
Huang, Yuan .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2008, 349 (1-2) :226-233
[9]  
CHIEN YW, 1987, CRC CR REV THER DRUG, V4, P67
[10]  
Chou KJ, 1997, BIOPHARM DRUG DISPOS, V18, P335, DOI 10.1002/(SICI)1099-081X(199705)18:4<335::AID-BDD22>3.0.CO